Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia

Jae-Ho Yoon, Hee-Je Kim, Dae-Hun Kwak, Gi June Min, Sung-Soo Park, Young-Woo Jeon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Woo-Sung Min

Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Background
Standard remission induction chemotherapy consisting of anthracycline plus cytarabine (3+7) is administered for adult acute myeloid leukemia (AML). However, the effects of intensified regimen on complete remission (CR), relapse and overall survival (OS) remain unknown.

Methods
We analyzed 1195 patients treated with idarubicin plus cytarabine/BHAC (3+7) from 2002 to 2013. Among them, 731 received early intensification with 3-day cytarabine/BHAC (3+10, N=363) or 2-day idarubicin plus cytarabine/BHAC 3 days (5+10, N=368). The 3+10 and 5+10 strategies were applied to patients with bone marrow blast counts of 5–20% and >20% on day 7 of 3+7, respectively.

Results
Early intensification correlated with a younger age (median: 40 vs. 45 yr) and higher t(8;21) frequency (20.4% vs. 7.1%), compared to 3+7. After early intensification, the early death rates were higher among the elderly (3+10 [15.7%], 5+10 [21.7%] vs. 3+7 [6.3%], P=0.038), while the post-induction CR rate was higher in young patients (3+10 [79.8%], 5+10 [75.1%] vs. 3+7 [65.1%], P<0.001). Early relapse rate was also decreased (3+10 [11.8%], 5+10 [11.7%] vs. 3+7 [22.0%], P<0.001). In multivariate analysis, early intensification correlated with an inferior 5-year OS among elderly patients (19.2% vs. 22.8%; hazard ratio [HR]=1.84, 95% confidence interval [CI]; 1.11–3.06, P=0.018) and lower overall relapse rate among young patients (33.0% vs. 41.4%, P=0.023; HR=0.71, 95% CI; 0.55–0.93, P=0.012).

Conclusion
Early intensification correlated with higher CR and lower relapse rates, but not OS in young AML patients. In elderly patients, early intensification correlated with a higher early death rate and poorer OS.

Key Words  Acute myeloid leukemia, Induction chemotherapy, Early intensification

INTRODUCTION

The current standard remission induction chemotherapy strategy for adult patients younger than 60 years with acute myeloid leukemia (AML) consisting of a continuous standard doses of cytarabine infusion (100–200 mg/m²) for 7 days combined with either idarubicin (12 mg/m² for 3 days) or daunorubicin (40–60 mg/m² for 3 days) [1, 2], has not changed considerably over the last 25 years. However, several previous trials have used novel agents or dose-escalation methods to intensify this induction regimen for improving the hematological complete remission (CR) rate and reducing the relapse rate, which would yield better survival outcomes.
Initially, different types or doses of anthracyclines were compared to evaluate possible improvements in clinical outcomes. A recent meta-analysis of 29 randomized controlled trials comparing the efficacies of daunorubicin and daunorubicin at different dosing schedules revealed that daunorubicin reduced the remission failure rate, as indicated by a risk ratio of 0.81 (95% confidence interval [CI]; 0.66-0.99, \( P=0.04 \)) only when the daunorubicin/idarubicin dose ratio was < 5, and did not significantly affect the outcomes of early death or overall mortality [3]. Few studies have reported a reduced remission failure rate with escalated doses of daunorubicin (60–90 mg/m²), compared to the standard dose (45 mg/m²) [4-6] or idarubicin [7]. Recent data also demonstrated the benefit of high-dose daunorubicin regardless of the cytogenetic risk, even in patients with the \( F L T 3- I T D \) and \( D N M T 3 A \) mutations [8]. Other studies have also evaluated high-dose cytarabine for induction therapy and revealed that intensified regimens increase the treatment-related mortality and toxicity rates in spite of benefits for some patient subgroups [9-11]. One prospective trial suggested that high-dose cytarabine yielded superior overall survival (OS) without excessive toxicity in younger patients and high-risk patients with high-risk cytogenetic profiles and/or the \( F L T 3-I T D \) mutation or those with secondary AML, whereas no benefits were observed for elderly patients [12]. A recent meta-analysis also showed that high-dose cytarabine improved survival outcomes and reduced relapses, particularly among AML patients with favorable-risk cytogenetic profiles; however, toxicity was a limiting factor [13].

The adult AML patients visiting our healthcare center were initially treated with a protocol comprising 3 days of idarubicin and 7 days of intermediate-dose cytarabine or \( N^{4} \)-behenoyl-1-β-D-arabinofuranosyl cytosine (BHAC). And then, they were administered early intensified induction therapy according to the bone marrow (BM) blast counts on day 7 of the initial chemotherapy regimen. We tried to identify the treatment outcomes associated with early intensification compared to those of the standard 3+7 regimen in Korean AML patients, with the aim of demonstrating the effect of additional cytarabine or dose-escalated idarubicin therapy.

**MATERIALS AND METHODS**

**Study population and initial diagnosis**

After excluding patients with acute promyelocytic leukemia, we retrospectively enrolled 1,195 adult AML patients who were initially treated with idarubicin-based intensive induction chemotherapy between 2002 and 2013. The diagnoses were established by morphological, cytochemical, immunophenotypic, and cytogenetic analyses of BM blast cells. For karyotyping, at least 20 metaphase cells were analyzed using the GTG banding method and the International System for Cytogenetic Nomenclature (ISCN) [14]. For the molecular analysis, we screened 28 genetic aberrations by multiplex reverse transcriptase polymerase chain reaction (RT-PCR) using the HemaVision Kit (DNA Technology, Aarhus, Denmark). Unfortunately, molecular studies, including the detection of \( N P M 1, C E B P a, F L T 3 \), and \( k i t \) mutations and of WT1 and BAALC expression, were not generally implemented before 2008. As a result, cases without molecular marker data were stratified according to the karyotype alone. For the final molecular cytogenetic risk-stratification, we divided patients into three subgroups according to the National Comprehensive Cancer Network (NCCN) guidelines [2]. This research was conducted in accordance with the Institutional Review Board and Ethics Committee guidelines of the Catholic Medical Center (approval number: KC17RESI0156) and the principles of the Declaration of Helsinki.

**Remission induction therapy and early intensification**

Fig. 1 shows the treatment strategy for adult AML used at the Catholic Blood and Marrow Transplantation Center in Korea. All patients were initially treated with 3+7 induction chemotherapy, comprising idarubicin (12 mg/m²) for 3 days plus cytarabine (100 mg/m²) or BHAC (300 mg/m²) for 7 days [15]. Of these patients, 731 (61.2%) additionally received continuous early intensification with cytarabine or BHAC for the following 3 days (3+10, N=363) or idarubicin for the following 2 days and cytarabine or BHAC for the following 3 days (5+10, N=368). Decisions for early intensification were based on the follow-up BM blast counts on day 7 of 3+7 induction chemotherapy; 3+10 intensification was administered for blast counts of 5–20% and 5+10 intensification was administered for blast counts > 20% (early intensification group). The remaining 464 patients with blast counts < 5% finished the 3+7 regimen without early intensification (standard group). For patients who achieved a hematological CR after induction, we applied our standard consolidation chemotherapy, which consisted of a 3+5 regimen comprising mitoxantrone (12 mg/m²) or idarubicin (12 mg/m²) for 3 days plus an intermediate dose of cytarabine (1.0 g/m² every 12 hr) or BHAC (300 mg/m²) for 5 days; these were alternatively applied. For patients who did not achieve remission, we administered re-induction chemotherapy, which comprised 4 days of mitoxantrone (10 mg/m²) and intermediate-dose cytarabine (1.0 g/m² every 12 hr), followed by 3 days of etoposide (100 mg/m²).

**Post-remission therapy**

For patients in CR, we searched for available donors for allogeneic-hematopoietic cell transplantation (HCT) during the consolidation period, giving initial preference to human leukocyte antigen (HLA)-matched sibling donors (MSDs), followed by HLA well-matched unrelated donors (URDs). When conventional donors were not available, we searched for haploidentical familial mismatched donors; if a patient refused allogeneic-HCT, we performed autologous-HCT or completed three cycles of consolidation chemotherapy alone according to the patient’s and physician’s joint decision [16-18]. If a patient was a candidate for autologous-HCT, CD34+ hematopoietic stem cells were collected for 3 days
during consolidation chemotherapy after the neutrophil count had recovered. For donor mobilization, we administered granulocyte-colony stimulating factor subcutaneously at a dose of 10 μg/kg/day for 4 days. Patients who underwent HCT received either a myeloablative (MAC) or a reduced-intensity (RIC) conditioning regimen. Briefly, the MAC regimen comprised cyclophosphamide (120 mg/kg) combined with total body irradiation (TBI; 1320 cGy) or busulfan (12.8 mg/kg). The autologous MAC regimen comprised TBI (1200 cGy) plus ARA-C (9 g/body surface area) and melphalan (100 mg/body surface area) [19]. For the RIC regimen, we administered busulfan (6.4 mg/kg) and fludarabine (150 mg/m²) with TBI (400 cGy) [20]. Anti-thymocyte globulin (ATG) at a dose of 2.5 mg/kg (1.25 mg/kg each on days -3 and -2) was administered to patients receiving stem cells from an URD. For haploidentical transplantation, we administered fludarabine (150 mg/m²) and busulfan (6.4 mg/kg) with TBI (800 cGy) and ATG (5 mg/kg in 1.25 mg/kg doses on days -4 to -1) [21].

**Statistical analysis**

This study was conducted to assess clinical outcomes according to induction chemotherapy intensity, and focused on early death (within 8 weeks), early relapse during or after the consolidation period before HCT, long-term overall survival (OS) and the cumulative incidence of overall relapse (CIR). All categorical variables were compared using a chi-squared analysis and Fisher’s exact test, and continuous variables were assessed using Student’s t-test and the Wilcoxon rank-sum test. OS was estimated using a Kaplan-Meier analysis, and a log-rank analysis was used to evaluate differences in survival between the groups. The cumulative incidence of early death or early relapse and the CIR were estimated using a cumulative incidence estimation method that treated relapse and non-relapse deaths as competing risks, and were compared using the Gray test [22]. A multivariate analysis based on the Cox proportional regression model was used to calculate survival hazard ratios, and the Fine-Gray proportional hazard regression model was used to calculate the hazard ratios for cumulative incidences. All statistical analyses were performed using “R” software (version 2.15.1; R Foundation for Statistical Computing, Vienna, Austria, 2012). Statistical significance was set at a P-value < 0.05.

**RESULTS**

**Baseline characteristics**

The baseline characteristics of the two subgroups according to the induction chemotherapy induction are shown in Table 1. The standard group (N = 464) and the early
Table 1. Baseline characteristics according to the intensity of induction chemotherapy.

|                      | Total (N=1,195) | Standard 3+7 (N=464) | Early intensification (N=731) | P     |
|----------------------|-----------------|----------------------|-----------------------------|-------|
| Age (range)          |                 |                      |                             |       |
| < 44 yr              | 213 (45.9%)     | 450 (61.5%)          |                             |       |
| ≥ 44–55 yr           | 139 (30.0%)     | 207 (28.3%)          |                             | 0.543 |
| ≥ 56 yr              | 112 (24.1%)     | 74 (10.1%)           |                             | <0.001|
| Gender (Male, %)     |                 |                      |                             |       |
|                      | 248 (53.4%)     | 412 (56.3%)          |                             | 0.324 |
|                      | 12.8 (0.3-83.0) | 13.4 (6.6-648.7)     |                             | 0.339 |
|                      | 30.0 (0.9-99)   | 44.0 (0-99)          |                             |       |
|                      | 7.30 (20-99)    | 81.0 (25-99)         |                             | <0.001|
|                      | 54.5 (5.0-491.0)| 50.0 (5.0-957.0)     |                             | 0.192 |
| NCCN risk stratification |                |                      |                             |       |
| Not assessed (N=18)  | 11 (2.4%)       | 7 (0.9%)             |                             | 0.141 |
| Favourable-risk (N=257)| 75 (16.2%)     | 182 (24.9%)          |                             | <0.001|
| Intermediate-risk (N=642)| 266 (57.3%) | 376 (51.4%)          |                             | <0.001|
| Adverse-risk (N=278) | 112 (24.1%)     | 166 (22.7%)          |                             | 0.047 |
| Induction chemotherapy regimen |            |                      |                             |       |
| Idarubicin plus ARA-C 3+7 | 181 (39.0%) | 181 (39.0%)          |                             |       |
| Idarubicin plus BHAC 3+7 | 283 (61.0%) | 283 (61.0%)          |                             |       |
| Idarubicin plus ARA-C 3+10 | 76 (10.4%) | 76 (10.4%)           |                             |       |
| Idarubicin plus BHAC 3+10 | 287 (39.2%) | 287 (39.2%)          |                             |       |
| Idarubicin plus ARA-C 5+10 | 84 (11.5%) | 84 (11.5%)           |                             |       |
| Idarubicin plus BHAC 5+10 | 284 (38.9%) | 284 (38.9%)          |                             |       |

Post-remission therapy (N=946) N=359 (77.4%) N=587 (80.3%)

Allogeneic-HCT (N=638) 257 (71.6%) 381 (64.9%) 0.033

Matched sibling (N=363) 143 (39.8%) 220 (37.4%) 0.710

Unrelated (N=203) 70 (19.5%) 133 (22.6%) 0.822

Familial mismatched (N=72) 44 (12.2%) 28 (4.8%) 0.001

Autologous-HCT (N=193) 42 (11.7%) 151 (25.7%) 0.001

Chemotherapy alone (N=115) 60 (16.7%) 55 (9.4%) 0.001

a) P < 0.05.
Abbreviations: APM, acute panmyelosis with myelofibrosis; ARA-C, cytarabine; BHAC, N4-behenoyl-1-β-D-arabinofuranosyl cytosine; BM, bone marrow; HCT, hematopoietic cell transplantation; MRC, myelodysplasia-related change; NOS, not otherwise specified; PB, peripheral blood.

---

Table 2. Early treatment outcomes according to the intensity of induction treatment.

|                      | Total (N=1,195) | Standard 3+7 (N=464) | Intensified 3+10 (N=363) | Intensified 5+10 (N=368) | P     |
|----------------------|-----------------|----------------------|--------------------------|--------------------------|-------|
| Post-induction early deathb) (N=57, 4.8%) | 21 (4.5%)      | 15 (4.1%)            | 21 (5.7%)                | 0.578     |
| ≤ 55 yr              | 14/352 (4.0%)  | 7/312 (2.2%)         | 2/74 (3.4%)              | 0.710     |
| > 55 yr              | 7/112 (6.3%)   | 8/31 (5.1%)          | 13/34 (9.1%)             | 0.822     |
| Favorable-risk       | 4/75 (5.3%)    | 2/74 (2.7%)          | 5/108 (4.6%)             | 0.701     |
| Intermediate-risk    | 10/266 (3.8%)  | 7/204 (3.4%)         | 8/172 (4.7%)             | 0.822     |
| Adverse-risk         | 6/112 (5.4%)   | 6/81 (7.4%)          | 8/85 (9.4%)              | 0.549     |
| CR after induction CTx (N=849, 71.0%) | 299 (64.4%) | 278 (76.6%)          | 272 (73.9%)              | <0.001   |
| ≤ 55 yr              | 229/352 (65.1%)| 249/312 (79.8%)      | 259/345 (75.1%)          | <0.001    |
| > 55 yr              | 70/112 (62.5%) | 29/51 (56.9%)        | 13/23 (56.5%)            | 0.736     |
| Favorable-risk       | 64/75 (85.3%)  | 70/74 (94.6%)        | 100/108 (92.6%)          | 0.107     |
| Intermediate-risk    | 169/266 (63.5%)| 154/204 (75.5%)      | 121/172 (70.3%)          | 0.019     |
| Adverse-risk         | 60/112 (53.6%) | 52/81 (64.2%)        | 51/85 (60.0%)            | 0.319     |
| Final CR achievement (N=967, 80.9%) | 364 (70.4%)  | 305 (84.0%)          | 298 (81.0%)              | 0.129     |
| ≤ 55 yr              | 285/352 (80.0%)| 271/312 (86.9%)      | 283/345 (82.8%)          | 0.102     |
| > 55 yr              | 79/112 (70.5%) | 34/51 (66.2%)        | 13/23 (65.2%)            | 0.816     |
| Favorable-risk       | 70/75 (93.3%)  | 71/74 (95.9%)        | 102/108 (94.4%)          | 0.780     |
| Intermediate-risk    | 207/266 (77.8%)| 169/204 (82.8%)      | 137/172 (79.7%)          | 0.402     |
| Adverse-risk         | 81/112 (72.3%) | 62/81 (76.5%)        | 58/85 (68.2%)            | 0.489     |
| Early relapse before HCT (N=151, 15.6%) | 80/364 (22.0%) | 36/305 (11.8%)       | 35/298 (11.7%)           | <0.001   |
| ≤ 55 yr              | 52/285 (18.2%) | 29/271 (10.7%)       | 32/283 (11.3%)           | 0.014     |
| > 55 yr              | 27/79 (34.2%)  | 7/34 (20.6%)         | 5/10 (19.0%)             | 0.095     |
| Favorable-risk       | 11/70 (15.7%)  | 1/71 (1.4%)          | 5/10 (4.9%)              | 0.002     |
| Intermediate-risk    | 42/207 (20.3%) | 20/169 (11.8%)       | 17/137 (12.4%)           | 0.041     |
| Adverse-risk         | 23/81 (28.4%)  | 14/62 (22.6%)        | 13/58 (22.4%)            | 0.638     |

b) Early death from any cause (with or without aplasia) within 56 days after chemotherapy.
Abbreviations: Allo, allogeneic; Auto, autologous; BM, bone marrow; CR, complete remission; CTx, chemotherapy; HCT, hematopoietic cell transplantation.

---

A abbreviations: APM, acute panmyelosis with myelofibrosis; ARA-C, cytarabine; BHAC, N4-behenoyl-1-β-D-arabinofuranosyl cytosine; BM, bone marrow; HCT, hematopoietic cell transplantation; MRC, myelodysplasia-related change; NOS, not otherwise specified; PB, peripheral blood.
intensification group (N=731) had median ages of 45 years (range, 17–75 yr) and 40 years (range, 17–69 yr), respectively (P<0.001). The early intensification group had a higher proportion of young patients (≤55 yr) (89.9% vs. standard: 75.9%, P<0.001). Furthermore, the early intensification group had a significantly higher peripheral blood blast count (44% vs. 30%, P=0.001), BM blast count (81% vs. 73%, P<0.001), and frequency of t(8;21) (20.4% vs. 7.1%, P<0.001). Among the 182 patients harboring t(8;21), 56.0% (N=102) had a BM blast count >20% and 25.8% (N=47) had a BM blast count of 5–20% on day 7 of induction chemotherapy and accordingly received early intensification therapy. In our cohort, overall 79.1% (N=946) of patients, consisting of 77.4% (N=359) of standard group and 80.3% (N=587) of early intensification group, received postremission therapy after achieving a CR (P=0.224). Significantly higher percentage of patients of standard group received allogeneic-HCT (71.6% vs. 64.9%, P=0.033) and repeated consolidation chemotherapy (16.7% vs. 9.4%, P=0.001).

### Initial treatments and early outcomes

We calculated the early death rate (up to 8 weeks after induction therapy), CR rate and early relapse rate before HCT according to the induction chemotherapy intensity (Table 2). The early death rate was 4.8% (N=47) and significantly higher in early intensification group, especially among patients older than 55 years (17.5% vs. 6.3%, P=0.015). A total of 849 (71.0%) patients achieved a CR after one cycle of induction chemotherapy, and 967 (80.9%) achieved a CR after re-induction chemotherapy. Although the final CR rates did not differ significantly even after early intensification, the CR rate after one cycle of induction chemotherapy was significantly higher in early intensification group (76.6%, 73.9% and 64.4% in the 3+10 group, 5+10 group and standard group, respectively, P<0.001) especially among patients younger than 55 years (79.8%, 75.1% and 65.1% in the 3+10 group, 5+10 group and standard group, respectively, P<0.001) and those in the intermediate-risk group (75.5%, 70.3% and 63.5% in the 3+10 group, 5+10 group and standard group, respectively, P=0.019). The overall early relapse rate before HCT was 15.6%, and significantly higher in early intensification group (84.9% vs. 73.9%, P<0.001) among patients older than 55 years (25.8% vs. 13.1%, P=0.001) and those in the intermediate-risk group (25.8% vs. 13.1%, P=0.001).
decreased in early intensification group (11.8%, 11.7% and 22.0% in the 3+10 group, 5+10 group and standard group, respectively, \( P<0.001 \)) except for adverse-risk group. In the favorable-risk group, the early relapse rate was significantly lower in early intensification group (1.4%, 4.9% and 15.7% in the 3+10 group, 5+10 group and standard group, respectively, \( P=0.002 \)). The early clinical outcomes were not significantly different between the two intensification groups. Although the cumulative incidence of early death did not significantly differ between the standard and early intensification groups (4.5% vs. 4.9%, \( P=0.768 \), Fig. 2A), the cumulative incidence of early relapse before HCT was significantly lower in early intensification group (11.8% vs. 20.9%, \( P<0.001 \), Fig. 2B). In the elderly group (\( >55 \) yr), however, the cumulative incidence of early death was significantly higher in the early intensification group (17.6% vs. 6.2%, \( P=0.014 \), Fig. 2C). In the young patient group (\( \leq 55 \) yr), although the early death rate did not significantly differ with respect to treatment intensity (3.5% vs. 4.0%, \( P=0.685 \)), the cumulative incidence of early relapse before HCT was significantly lower after early intensification (11.0% vs. 18.9%, \( P=0.005 \), Fig. 2D). As shown in Table 3, the multivariate analysis identified that early intensification significantly increased early death rate in the elderly group (HR=2.76, 95% CI: 1.03–7.35, \( P=0.042 \)) and significantly reduced early relapse rate before HCT only in the young patient group (HR=0.54, 95% CI: 0.37–0.79, \( P=0.001 \)).

### Overall treatment outcomes

Overall, early intensification was associated with a superior 5-year OS (44.4% vs. 37.4%, \( P=0.035 \), Fig. 3A) and lower relapse rate (33.6% vs. 42.7%, \( P=0.010 \), Fig. 3B), compared with standard treatment during a median follow-up of 54.5 months (range, 5.8–143.8). In the elderly group, early intensification correlated with early death and, consequently, an inferior 5-year OS (19.2% vs. 22.8%, \( P=0.014 \), Fig. 3C), as confirmed by the multivariate analysis (HR=1.84, 95% CI: 1.11–3.06, \( P=0.018 \)). In contrast, early intensification

---

**Table 3. Multivariate analysis to identify the factors affecting early treatment outcomes and OS.**

| Variables                             | Early death rate (EDR) | Early relapse (CIR) before HCT | Overall survival (OS) |
|----------------------------------------|------------------------|----------------------------------|-----------------------|
|                                        | 8-weeks EDR            | Multivariate                     | 5-year CIR           | Multivariate | 5-year OS            | Multivariate |
|                                        | \( p \)                | \( HR \) (95% CI)                | \( p \)               | \( HR \) (95% CI) | \( p \)               | \( HR \) (95% CI) | \( p \)       |
| Elderly group (\( >55 \) yr) Intensity of induction CTx<br>Standard therapy 3+7 | 6.2% 0.014<sup>a</sup> | 1                                | 41.5% 0.073          | 22.8% 0.014<sup>a</sup> | 1                        | 1                        | 0.018<sup>a</sup> |
| Early intensification                   | 17.6% 2.76 0.042<sup>a</sup> | (1.03–7.35)                      | 20.4%                | 19.2% 1.84<sup>a</sup> | (1.11–3.06)               |                      |
| Induction regimen<br>BHAC-based        | 12.9% 0.341            | 22.0% 0.044<sup>a</sup>          | 19.0% 0.006<sup>a</sup> |                      |                      |
| ARA-C-based                            | 8.2% 0.700             | 46.2%                            | 22.3%                |                      |                      |
| NCCN group Good to intermediate-risk   | 7.2% 0.015<sup>a</sup> | 27.3% 0.376                      | 28.4% 0.001<sup>a</sup> |                      |                      |
| Adverse-risk                           | 19.2% 0.533            | 37.6%                            | 12.1%                |                      |                      |
| Leukocyte count at diagnosis<br>&lt;50,000/µL | 9.8% 0.533            | 30.0% 0.979                      | 25.2% 0.728          |                      |                      |
| ≥50,000/µL                             | 13.2% 0.533            | 30.5%                            | 17.7%                |                      |                      |
| HCT                                    | –                      | –                                | –                    | –                      | –                      |
|                                     | –                      | <0.001<sup>a</sup>               | 0.21                 | <0.001<sup>a</sup>   |
| Young group (\( \leq 55 \) yr) Intensity of induction CTx<br>Standard therapy 3+7 | 4.0% 0.685            | 18.9% 0.005<sup>a</sup>          | 41.0% 0.047<sup>a</sup> |                      |                      |
| Early intensification                   | 3.5% 0.700             | 11.0%                            | 47.3%                |                      |                      |
| Induction regimen<br>BHAC-based        | 3.8% 0.700             | 10.9% 0.003<sup>a</sup>          | 48.1% 0.020<sup>a</sup> |                      |                      |
| ARA-C-based                            | 3.4% 0.700             | 19.6%                            | 38.1%                |                      |                      |
| NCCN group Good to intermediate-risk   | 3.5% 0.512             | 11.0% &lt;0.001<sup>a</sup>      | 51.8% &lt;0.001<sup>a</sup> |                      |                      |
| Adverse-risk                           | 4.4% 0.419             | 23.6% 1.49 (1.22–1.82)           | 22.0% 1.54 (1.37–1.73) |                      |                      |
| Leukocyte count at diagnosis<br>&lt;50,000/µL | 3.6% 0.419             | 11.8% 0.021<sup>a</sup>          | 44.8% 0.728          |                      |                      |
| ≥50,000/µL                             | 2.5% 17.6%             | 11.8% 0.021<sup>a</sup>          | 44.8% 0.728          |                      |                      |
| HCT                                    | –                      | –                                | –                    | –                      | –                      |
|                                     | –                      | 0.19                             | <0.001<sup>a</sup>   |

<sup>a</sup>\( P<0.05 \).

Abbreviations: CTx, chemotherapy; HCT, hematopoietic cell transplantation; HR, hazard ratio.
correlated with a reduced rate of early relapse and, consequently, a superior 5-year OS (47.3% vs. 41.0%, \( P=0.047 \), Fig. 3D) and reduced 5-year overall relapse rate (33.0% vs. 41.4%, \( P=0.023 \)) in the young patient group. In multivariate analysis, only the factors including early intensification (HR=0.71, 95% CI: 0.55–0.93, \( P=0.012 \)), intermediate-to-favorable molecular cytogenetics (HR=0.38, 95% CI: 0.29–0.48, \( P<0.001 \)) and HCT (HR=0.25, 95% CI: 0.17–0.37, \( P<0.001 \)) were associated with a lower overall relapse rate, while no significant effect of early intensification on long-term OS was confirmed (Table 3).

**DISCUSSION**

Our current study demonstrated that early intensification with additional cytarabine or BHAC for 3 days, with or without an additional 2 days of idarubicin therapy, was associated with a higher early death rate and inferior OS in elderly group, despite higher post-induction CR rate and lower early relapse rate before HCT. However, both univariate and multivariate analysis showed that early intensification was associated with lower overall relapse rate in young patient group. In addition, early-intensification had no effect on clinical outcome in adverse-risk group. Therefore, we suggest that early intensification may benefit young patients without an adverse-risk molecular cytogenetic profile. Among patients in the adverse-risk category, clinical trials should first consider the use of several novel FLT3-ITD or c-kit mutation-targeting agents before proceeding to allogeneic-HCT.

We mainly selected BHAC, widely used in Japan due to lower incidence of toxicities such as nausea and vomiting, as initial chemotherapy regimen [23]. Owing to its lower CR rate and poorer survival outcome compared to cytarabine [24], we attempted to intensify the induction regimen by adding 3 further days of BHAC with or without 2 days of idarubicin therapy, according to the BM blast count on the final chemotherapy infusion day during the initial 3+7 regimen. However, we mainly replaced BHAC with cytarabine within the same intensification strategy since 2009. We found that our current results were mainly affected by the outcomes of treatment with the intensification strategy comprising BHAC plus idarubicin, which was associated

---

**Fig. 3.** Overall survival (OS) and overall relapse rates according to the intensity of induction chemotherapy. (A) OS. (B) Overall cumulative incidence of relapse. (C) OS in the elderly patients (older than 55 yr). (D) OS in patients younger than 55 years.
with a relatively lower early death rate (12.2% in 3+10 and 18.8% in 5+10) even in the elderly group (Supplementary Table 1). In comparison, cytarabine-based intensification did not increase the post-induction CR rate, but was associated with higher early death rates (30.0% in 3+10 and 28.6% in 5+10) in the elderly group and lower early relapse rates in the favorable-risk group (Supplementary Table 2). Therefore, BHAC-based intensification might be more appropriate than cytarabine-based intensification, which yielded increased rates of toxicity and non-relapse mortality in the elderly patients.

Our data showed that AML patients with the t(8;21) mutation were more likely to receive early intensification as a result of high remnant BM blast counts on day 7 of the 3+7 chemotherapy regimen, suggesting their late blast clearance, although t(8;21) is considered a favorable-risk cytogenetic marker. However, all patients with favorable-risk cytogenetics had an optimal response (blast ≤5%) and completed induction therapy without double induction on day 14 of induction chemotherapy. Several previous reports showed correlations of an early BM blast clearance with a higher CR rate and better survival outcomes [25-27], and many guidelines suggest that a second induction is recommended for patients with high remnant BM blasts on day 14 of induction chemotherapy. Therefore, our BM blast evaluation on day 7 was too early to predict the clinical outcomes for some patients such as those with the t(8;21) mutation. Nevertheless, our current study revealed that the administration of early intensification based on this earlier BM blast evaluation might be an acceptable remission induction strategy for young patients with intermediate-to-favorable-risk molecular cytogenetics, particularly with regard to a higher CR rate and lower early relapse rate. Given our experiences with a very long neutropenic period and higher mortality associated with additional 3+7 chemotherapy according to the BM blast count on day 14, it seems that the well-known Western protocol might be very toxic for Asian (and specifically Korean) patients. Therefore, based on our current results, we are currently planning a well-designed prospective trial to prove the role of BM blast evaluation on day 7 and the usefulness of early intensification for selected groups of AML patients.

After the consolidation chemotherapy comprising intermediate-dose cytarabine or BHAC combined with idarubicin, the patients underwent allogeneic-HCT when a well matched donor was available. Otherwise, the patients underwent autologous-HCT followed by chemotherapy alone or haploidentical HCT. Although high-dose cytarabine was recommended a standard consolidation regimen for patients younger than 60 years with intermediate-to-favorable-risk cytogenetics [28], we used an intermediate dose of cytarabine due to the risks of neurologic toxicity and non-relapse mortality associated with high-dose cytarabine and previous reports that demonstrated similar treatment outcomes with intermediate-dose cytarabine [29, 30].

Considering the effects of consolidation therapy on survival and many confounding parameters in HCT, it is difficult to properly evaluate the long-term survival outcomes of each induction regimens. However, we expect that the high post-induction CR rate and lower early death rate of early intensification in the young patient group might increase the likelihood for undergoing HCT leading to better disease-free survival. Unfortunately, however, early intensification did not significantly improve survival outcomes, although it significantly reduced the early relapse rate before HCT without increasing the early death rate.

Although this study was a retrospective analysis of data collected from a heterogeneous cohort over a long period, our observations were based on a consistent (i.e., largely unchanging over time) treatment strategy including consolidation chemotherapy, donor searching, pre-HCT conditioning regimens, immunosuppressive agents and supportive management. In conclusion, we suggest that early intensification may benefit young patients, especially those who have been treated with a BHAC-based regimen, and could result in a higher CR rate and lower relapse rate. However, this early intensification should not be applied to the elderly patients treated with a cytarabine-based regimen or patients with adverse-risk molecular cytogenetics.

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

REFERENCES

1. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia (Version 1.2016). Fort Washington, PA: National Comprehensive Cancer Network, 2016. (Accessed March 5, 2017, at https://www.nccn.org/professionals/physician_gls/PDF/aml.pdf).
3. Teuffel O, Leibundgut K, Lehnbecher T, Alonzo TA, Beyene J, Sung L. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 2013;161:192-203.
4. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249-59.
5. Lee JH, Joo YD, Kim H, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 2011;118:3832-41.
6. Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m² vs 60 mg/m² in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 2015;125:3878-85.
7. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin
16. Yoon JH, Kim HJ, Park SS, et al. Long-term clinical outcomes of autologous hematopoietic cell transplantation using modified TAM or combination of triple-alkylating agents conditioning regimens as one of the post-remission treatments in patients with adult acute myeloid leukemia in first complete remission. Bone Marrow Transplant 2004;34:215-20.
17. Lee SE, Kim HJ, Min WS, et al. Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities. Int J Hematol 2010;92:342-50.
18. Cho BS, Yoon JH, Shin SH, et al. Comparison of allogeneic stem cell transplantation from familial-mismatched/haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.
19. Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group. Haematologica 2004;89:408-18.
20. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.
21. Fukushima T, Uragami M, Yamauchi M, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88:2841-51.
22. Kern W, Haferlach T, Schoch C, et al. A new prognostic score for acute myelogenous leukemia. Biol Blood Marrow Transplant 2012;18:1552-63.
23. Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003;101:64-70.
24. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.
25. Fukushima T, Uragami M, Yamauchi M, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88:2841-51.
26. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710-7.
27. Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group. Haematologica 2004;89:408-18.
28. Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003;101:64-70.
29. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.